HPV genotypes detected in cervical cancers from Alaska Native women, 1980–2007

• Other Authors: Kelly, Janet J., Unger, Elizabeth R., Dunne, Eileen F., Murphy, Neil J., Tiesinga, James, Koller, Kathy R., Swango-Wilson, Amy, Philemonof, Dino, Lounmala, Xay, Markowitz, Lauri E., Steinau, Martin, Hennessy, Thomas
• Language: unknown
• Subjects: Supplement 1; 2013; Alaska Native; HPV; cervical cancer; HPV genotypes; Circumpolar Health; Alaska
• Online Access: http://stacks.cdc.gov/view/cdc/21084/

Background Human papillomavirus (HPV) vaccine prevents cervical pre-cancers and cancers caused by HPV types 16 and 18. This study provides information on the HPV types detected in cervical cancers of Alaska Native (AN) women. Methods Cases of invasive cervical cancer diagnosed in AN women aged 18 and above between 1980 and 2007 were identified from the Alaska Native Tumor Registry. A representative formalin-fixed, paraffin-embedded archived pathology block was retrieved and serially sectioned to allow histologic confirmation of lesion (first and last sections) and PCR testing of intervening sections. Extracted DNA was tested for HPV using Linear Array HPV Genotyping Test (Roche Diagnostics) with additional INNO-LiPA HPV Genotyping Assay (Innogenetics) testing on negative or inadequate specimens. All specimens were tested for a minimum 37 HPV types. Results Of 62 cervical cancer specimens evaluated, 57 (91.9%) contained one or more HPV types. Thirty-eight (61.2%) cancers contained HPV types 16 or 18, and 18 (29%) contained an oncogenic type other than type 16 or 18. Conclusions Overall, almost two-thirds (61.2%) of the archived cervical cancers had detectible HPV types 16 or 18, a finding similar to studies of US women. As expected, a proportion of cancers would not be prevented by the current vaccines. HPV vaccination and cervical cancer screening are important prevention strategies for AN women.